About this trial
The purpose of the study is to understand the effect of nicotinamide mononucleotide (NMN) on patients with diminished ovarian reserve and the outcomes of IVF/ICSI-ET.
Eligibility criteria
Qualifiers
Individuals who are 20 to 40 years old.
The concentrations of anti-Mullerian hormone < 1.1 ng/ml,
the values of antral follicle count was less than 7
serum concentrations of day-3 follicle-stimulating hormone (FSH): 10 IU/L ≤ FSH<20 IU/L
Disqualifiers
Individuals who are during pregnant, lactation or menopause.
Individuals who had non-46-XX karyotype, or attributed to known genetic etiology.
Cancer patients or receiving chemo/radiotherapy treatment within the past 5 years.
Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.
Trial design
Treatments tested in this trial
- NMN
- Placebo
Treatment groups
Locations
1Sponsors and collaborators
Peking University Third Hospital
Lead sponsor